Profusa soars after agreeing to buy PanOmics diagnostics platform

Profusa

06/04/2026 15:55

Updates

** Shares of digital health firm Profusa PFSA.O jump about two-fold to $1.77

** Co says it has signed a letter of intent to acquire BioInsights’ PanOmics molecular diagnostics platform in a roughly $30 million all-stock deal

** Says deal gives Profusa exclusive rights to the technology, plus access to clinical samples to validate new diagnostic tests

** Adds first focus area will be pancreatic cancer, a hard-to-treat cancer often needing complex surgery

** Says it is expanding work with Mayo Clinic to monitor patients before and after pancreatic surgeries using the platform

** BioInsights to nominate a Profusa board member, receive 3% royalty on net revenue from PanOmics - PFSA

** PFSA says it plans to raise additional funding to scale the diagnostics business

** Including session's moves, PFSA down ~90% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))